ubiquinone and Migraine-Disorders

ubiquinone has been researched along with Migraine-Disorders* in 32 studies

Reviews

16 review(s) available for ubiquinone and Migraine-Disorders

ArticleYear
Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.
    BMJ open, 2021, 01-05, Volume: 11, Issue:1

    To determine the effects of coenzyme Q10 (CoQ10) for reduction in the severity, frequency of migraine attacks and duration of headache in adult patients with migraine.. Systematic review and meta-analysis.. Cochrane Central Register of Controlled Trials, CENTRAL, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Psychological Information Database (PsycINFO) from inception till December 2019.. All randomised control trials comparing CoQ10 with placebo or used as an adjunct treatment included in this meta-analysis. Cross-over designs and controlled clinical trials were excluded.. Heterogeneity at face value by comparing populations, settings, interventions and outcomes were measured and statistical heterogeneity was assessed by means of the I. Six studies with a total of 371 participants were included in the meta-analysis. There is no statistically significant reduction in severity of migraine headache with CoQ10 supplementation. CoQ10 supplementation reduced the duration of headache attacks compared with the control group (MD: -0.19; 95% CI: -0.27 to -0.11; random effects; I. CoQ10 appears to have beneficial effects in reducing duration and frequency of migraine attack.. CRD42019126127.

    Topics: Adult; Dietary Supplements; Humans; Migraine Disorders; Ubiquinone

2021
Coenzyme Q
    Nutrients, 2021, May-17, Volume: 13, Issue:5

    Coenzyme Q

    Topics: Biological Availability; Dietary Supplements; Humans; Migraine Disorders; Neoplasms; Neurodegenerative Diseases; Neuromuscular Diseases; Quality of Life; Ubiquinone

2021
Energy Metabolism Impairment in Migraine.
    Current medicinal chemistry, 2019, Volume: 26, Issue:34

    Migraine is a common disabling neurological disorder which is characterised by a recurring headache associated with a variety of sensory and autonomic symptoms. The pathophysiology of migraine remains not entirely understood, although many mechanisms involving the central and peripheral nervous system are now becoming clear. In particular, it is widely accepted that migraine is associated with energy metabolic impairment of the brain. The purpose of this review is to present an updated overview of the energy metabolism involvement in the migraine pathophysiology. Several biochemical, morphological and magnetic resonance spectroscopy studies have confirmed the presence of energy production deficiency together with an increment of energy consumption in migraine patients. An increment of energy demand over a certain threshold creates metabolic and biochemical preconditions for the onset of the migraine attack. The defect of oxidative energy metabolism in migraine is generalized. It remains to be determined if the mitochondrial deficit in migraine is primary or secondary. Riboflavin and Co-Enzyme Q10, both physiologically implicated in mitochondrial respiratory chain functioning, are effective in migraine prophylaxis, supporting the hypothesis that improving brain energy metabolism may reduce the susceptibility to migraine.

    Topics: Brain; Energy Metabolism; Humans; Magnesium; Magnetic Resonance Spectroscopy; Migraine Disorders; Mitochondria; Oxidative Phosphorylation; Riboflavin; Ubiquinone

2019
Efficacy of CoQ10 as supplementation for migraine: A meta-analysis.
    Acta neurologica Scandinavica, 2019, Volume: 139, Issue:3

    Migraine ranks among the most frequent neurological disorders globally. Co-enzyme Q10 (CoQ10) is a nutritional agent that might play a preventative role in migraine. This meta-analysis aimed to investigate the effects of CoQ10 as a supplemental agent in migraine.. Web of Science, PubMed, and Cochrane Library were searched for potential articles that assessed the effects of CoQ10 on migraine. Data were extracted by two independent reviewers and analyzed with Revman 5.2 software (The Nordic Cochrane Centre, Copenhagen, Denmark).. We included five studies with 346 patients (120 pediatric and 226 adult subjects) in the meta-analysis. CoQ10 was comparable with placebo with respect to migraine attacks/month (P = 0.08) and migraine severity/day (P = 0.08). However, CoQ10 was more effective than placebo in reducing migraine days/month (P < 0.00001) and migraine duration (P = 0.009).. This is the first study to demonstrate the effects of CoQ10 supplementation on migraine. The results support the use of CoQ10 as a potent therapeutic agent with respect to migraine duration and migraine days/month. Nonetheless, more studies are needed to support the conclusions.

    Topics: Adult; Denmark; Humans; Migraine Disorders; Ubiquinone

2019
Usefulness of nutraceuticals in migraine prophylaxis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017, Volume: 38, Issue:Suppl 1

    Several studies have supported the efficacy of complementary and alternative medicine approaches (physical, behavioral and nutraceutical therapies) in the treatment of headache disorders. Nutraceutical treatment consists of taking vitamins, supplements (magnesium, riboflavin, coenzyme Q10, and alpha lipoic acid) and herbal preparations (feverfew and butterbur), and its usage is frequently determined by dissatisfaction with conventional medical therapies. There is a growing body of research on nutraceutical use for migraine prophylaxis. This brief overview provides information about the potential efficacy and side effects of various nutraceutical products summarizing randomized controlled trials of some of the most commonly used non-pharmacological treatments for the prophylaxis and treatment of migraine, including magnesium, coenzyme Q10, riboflavin (vitamin B

    Topics: Dietary Supplements; Humans; Magnesium; Melatonin; Migraine Disorders; Pre-Exposure Prophylaxis; Riboflavin; Tanacetum parthenium; Ubiquinone

2017
Nutraceuticals in the prophylaxis of pediatric migraine: Evidence-based review and recommendations.
    Cephalalgia : an international journal of headache, 2014, Volume: 34, Issue:8

    The literature on complementary and alternative medicine (CAM) is expanding. One of the most common conditions for which CAM is studied in the pediatric population is migraine. Nutraceuticals are a form of CAM that is being used for pediatric migraine prophylaxis.. A literature search was carried out in order to identify both observational studies and randomized controlled trials on the use of nutraceuticals for the prophylaxis of pediatric migraine. Adult studies on included nutraceuticals were also reviewed.. Thirty studies were reviewed on six different nutraceuticals: butterbur, riboflavin, ginkgolide B, magnesium, coenzyme Q10 and polyunsaturated fatty acids.. Overall, the quality of the evidence for the use of nutraceuticals in pediatric migraine prophylaxis is poor. Further research needs to be done in order to study the efficacy of nutraceuticals for the prophylaxis of pediatric migraine.

    Topics: Child; Dietary Supplements; Evidence-Based Medicine; Fatty Acids, Unsaturated; Ginkgolides; Humans; Lactones; Magnesium; Migraine Disorders; Observational Studies as Topic; Petasites; Randomized Controlled Trials as Topic; Riboflavin; Treatment Outcome; Ubiquinone

2014
CoEnzyme Q10 and riboflavin: the mitochondrial connection.
    Headache, 2012, Volume: 52 Suppl 2

    We conducted a short review of relevant literature which contends that migraine is associated with a wide-spread metabolic abnormality of mitochondrial oxidative metabolism, leading to the use of riboflavin and coenzyme Q10 as prophylactic therapy for migraine.. Riboflavin and coenzyme Q10 supplementation has been recommended widely as safe and effective prophylactic therapy for migraine. The background neurophysiological studies that led to the development of this therapy, which are extremely complex, deserve wider distribution.. A brief review of the relevant literature was conducted and summarized.. Brain energy metabolism in migraine has been found to be abnormal in all types of migraine, making the migrainous brain hyper-responsive to many stimuli. The metabolic abnormalities are more severe in the more-severe types of migraine, such as hemiplegic migraine and migrainous stroke, but they are present both during and between attacks. The metabolic abnormality in migraine extends beyond the brain to platelets and muscles, as proven by techniques of biochemistry, muscle morphology, and nuclear magnetic spectroscopy. There are strong similarities between migraine and certain inborn errors of metabolism, the metabolic encephalomyopathies, in which patients suffer genetic abnormalities in mitochondrial energy production to produce lactic acidosis, stroke, and migraine headaches. The theory of migraine as a mitochondrial disorder seems to have abundant evidence. However, aside from the genetic abnormalities discovered for the familial hemiplegic migraines, molecular genetic studies in migraine have been negative until recently, when whole genome sequencing has now reported positive results.. Arising from these extensive neurophysiological studies, the treatment of metabolic encephalomyopathies with pharmacological doses of riboflavin and coenzyme Q10 has shown positive benefits. The same treatment has now been applied to migraine, adding clinical support to the theory that migraine is a mitochondrial disorder.

    Topics: Brain; Energy Metabolism; Humans; Migraine Disorders; Mitochondria; Riboflavin; Ubiquinone

2012
Treatment of pediatric and adolescent migraine.
    Pediatric annals, 2010, Volume: 39, Issue:7

    Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents; Biofeedback, Psychology; Child; Dietary Supplements; Histamine Antagonists; Humans; Micronutrients; Migraine Disorders; Selective Serotonin Reuptake Inhibitors; Ubiquinone

2010
Coenzyme Q10.
    The Medical letter on drugs and therapeutics, 2006, Feb-27, Volume: 48, Issue:1229

    Topics: Amyotrophic Lateral Sclerosis; Antioxidants; Clinical Trials as Topic; Coenzymes; Costs and Cost Analysis; Heart Failure; Humans; Hypertension; Migraine Disorders; Mitochondrial Encephalomyopathies; Parkinson Disease; Ubiquinone

2006
"Natural" or alternative medications for migraine prevention.
    Headache, 2006, Volume: 46, Issue:6

    Topics: Antioxidants; Coenzymes; Complementary Therapies; Female; Herbal Medicine; Humans; Magnesium; Melatonin; Migraine Disorders; Petasites; Riboflavin; Tanacetum parthenium; Ubiquinone; Vitamin B Complex

2006
Migraine preventive therapy: current and emerging treatment options.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2005, Volume: 26 Suppl 2

    In this paper we review new treatment options for migraine prevention. We start with an overview about migraine and then briefly discuss current indications for migraine prevention and new and emerging preventive medications.

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Anticonvulsants; Antidepressive Agents; Antihypertensive Agents; Calcium Channel Blockers; Coenzymes; Drug Therapy; Humans; Levetiracetam; Lisinopril; Migraine Disorders; Petasites; Piperazines; Piracetam; Preventive Medicine; Triazoles; Ubiquinone

2005
Clinical aspects of coenzyme Q10: an update.
    Current opinion in clinical nutrition and metabolic care, 2005, Volume: 8, Issue:6

    Coenzyme Q10 is administered for an ever-widening range of disorders, therefore it is timely to illustrate the latest findings with special emphasis on areas in which this therapeutic approach is completely new. These findings also give further insight into the biochemical mechanisms underlying clinical involvement of coenzyme Q10.. Cardiovascular properties of coenzyme Q10 have been further addressed, namely regarding myocardial protection during cardiac surgery, end-stage heart failure, pediatric cardiomyopathy and in cardiopulmonary resuscitation. The vascular aspects of coenzyme Q10 addressing the important field of endothelial function are briefly examined. The controversial issue of the statin/coenzyme Q10 relationship has been investigated in preliminary studies in which the two substances were administered simultaneously. Work on different neurological diseases, involving mitochondrial dysfunction and oxidative stress, highlights some of the neuroprotective mechanisms of coenzyme Q10. A 4-year follow-up on 10 Friedreich's Ataxia patients treated with coenzyme Q10 and vitamin E showed a substantial improvement in cardiac and skeletal muscle bioenergetics and heart function. Mitochondrial dysfunction likely plays a role in the pathophysiology of migraine as well as age-related macular degeneration and a therapy including coenzyme Q10 produced significant improvement. Finally, the effect of coenzyme Q10 was evaluated in the treatment of asthenozoospermia.. The latest findings highlight the beneficial role of coenzyme Q10 as coadjuvant in the treatment of syndromes, characterized by impaired mitochondrial bioenergetics and increased oxidative stress, which have a high social impact. Besides their clinical significance, these data give further insight into the biochemical mechanisms of coenzyme Q10 activity.

    Topics: Antioxidants; Cardiovascular Diseases; Coenzymes; Friedreich Ataxia; Humans; Macular Degeneration; Migraine Disorders; Mitochondria; Oxidative Stress; Ubiquinone

2005
Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis.
    Vitamins and hormones, 2004, Volume: 69

    Migraine is a neurovascular syndrome characterized by recurrent headache associated with other symptoms, eventually preceded by aura. This chapter reviews the involvement of some mineral, coenzyme, and vitamin defects in the pathogenesis of migraine headaches and focuses on their potential therapeutic use in the preventive treatment for migraine. The therapeutic potential of magnesium, coenzyme Q(10), riboflavin, and vitamin B(12) can be cautiously inferred from some published open clinical trials; it should, however, be considered that double-blind randomized larger studies are needed to correctly estimate the impact of the placebo effect in these promising therapies.

    Topics: Adult; Antioxidants; Coenzymes; Female; Homocysteine; Humans; Magnesium; Male; Migraine Disorders; Riboflavin; Ubiquinone; Vitamin B 12

2004
Preventive migraine therapy: what is new.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2004, Volume: 25 Suppl 3

    In this paper we review new treatment options for migraine prevention. Because we focus on new drugs, some of the data we present herein were acquired in well design double blind, controlled studies, while the efficacy of other medication is supported only by open, uncontrolled trials (noted in the text wherever appropriate).

    Topics: Analgesics; Angiotensin-Converting Enzyme Inhibitors; Antidepressive Agents, Second-Generation; Antioxidants; Benzimidazoles; Biphenyl Compounds; Botulinum Toxins; Clonidine; Coenzymes; Fructose; Humans; Lisinopril; Migraine Disorders; Neuroprotective Agents; Petasites; Phytotherapy; Piperazines; Tetrazoles; Topiramate; Triazoles; Ubiquinone

2004
[Mitochondrial dysfunction in migraine].
    Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 4

    Topics: Coenzymes; Diagnosis, Differential; DNA, Mitochondrial; Humans; MELAS Syndrome; Migraine Disorders; Mutation; Prognosis; RNA; RNA, Mitochondrial; RNA, Transfer; Thiamine; Ubiquinone

2002
[THERAPEUTICS IN 1963].
    La Revue du praticien, 1963, Dec-21, Volume: 13

    Topics: Anticoagulants; Anticonvulsants; Antitoxins; Bone Diseases; Calcium; Cardiovascular Agents; Drug Therapy; Ergot Alkaloids; Gynecology; Insulin Antibodies; Methysergide; Migraine Disorders; Monoamine Oxidase Inhibitors; Nutritional Physiological Phenomena; Nutritional Sciences; Propiophenones; Selective Serotonin Reuptake Inhibitors; Serotonin; Toxins, Biological; Ubiquinone

1963

Trials

9 trial(s) available for ubiquinone and Migraine-Disorders

ArticleYear
The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial.
    Nutritional neuroscience, 2021, Volume: 24, Issue:4

    Topics: Adult; Biomarkers; Curcumin; Dietary Supplements; Double-Blind Method; Female; Humans; Inflammation; Male; Migraine Disorders; Neuroprotective Agents; Oxidative Stress; Quality of Life; Ubiquinone

2021
The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial.
    Cephalalgia : an international journal of headache, 2019, Volume: 39, Issue:5

    The present study aimed to determine the effects of combined supplementation of Coenzyme Q10 with L-carnitine on mitochondrial metabolic disorders marker and migraine symptoms among migraine patients.. A total of 56 men and women, between 20-40 years of age with migraine headache, participated in this randomized, double-blind, placebo-controlled, parallel study. The subjects were randomly assigned to receive either 30 mg/day Coenzyme Q10 and 500 mg/day L-carnitine at the same time and/or placebo tablets for 8 weeks. The measurements were completed at the beginning and end of the study. The primary outcome was severity of headache attacks. The secondary outcomes included duration, frequency of headache attacks, the headache diary results (HDR), and serum levels of lactate.. A significant reduction was obtained in serum levels of lactate (-2.28 mg/dl, 95% CI: -3.65, -0.90; p = 0.002), severity (-3.03, 95% CI: -3.65, -2.40; p ≤ 0.001), duration (-7.67, 95% CI: -11.47, -3.90; p ≤ 0.001), frequency (-5.42, 95% CI: -7.31, -3.53; p ≤ 0.001) and HDR (-103.03, 95% CI: -145.76, -60.29; p ≤ 0.001) after 8 weeks.. This double-blind parallel study provides evidences supporting the beneficial effects of Coenzyme Q10 and L-carnitine supplements on serum levels of lactate and migraine symptoms.. IRCT20121216011763N21.

    Topics: Adult; Carnitine; Dietary Supplements; Double-Blind Method; Female; Humans; Lactic Acid; Male; Migraine Disorders; Ubiquinone; Young Adult

2019
Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial.
    Acta neurologica Belgica, 2017, Volume: 117, Issue:1

    Despite the huge health and economic burden of migraine headache, few medications have been approved for its prophylactic treatment, most of which can potentially induce serious adverse effects. Coenzyme Q10 (CoQ10) is a supplement and has shown preliminary benefits in migraine prophylaxis. We aimed to assess this effect in an adult population. This is an open-label, parallel, add-on, match-controlled trial. Eighty patients diagnosed with migraine headache based on International Headache Society criteria were allocated to receiving only their current preventive drugs or their current preventive drugs plus 100 mg CoQ10 daily, matching for their baseline characteristics, and were assessed for frequency and severity of attacks, and ≥50 % reduction in attack frequency per month. Thirty-six and 37 patients were analyzed in CoQ10 and control groups, respectively. Number of attacks per month dropped significantly in the CoQ10 group (mean decrease: 1.6 vs. 0.5 among CoQ10 and control groups, respectively, p < 0.001). A significant reduction was also evident in the severity of headaches (mean decrease: 2.3 vs. 0.6 among CoQ10 and control groups, respectively, p < 0.001). For ≥50 % reduction in the frequency of attacks per month, the number needed to treat was calculated as 1.6. No side effects for CoQ10 were observed. This study suggests that CoQ10 might reduce the frequency of headaches, and may also make them shorter in duration, and less severe, with a favorable safety profile.

    Topics: Adult; Analgesics; Drug Therapy, Combination; Female; Humans; Male; Migraine Disorders; Ubiquinone; Vitamins

2017
Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial.
    The journal of headache and pain, 2015, Volume: 16

    Non-medical, non-pharmacological and pharmacological treatments are recommended for the prevention of migraine. The purpose of this randomized double-blind placebo controlled, multicenter trial was to evaluate the efficacy of a proprietary nutritional supplement containing a fixed combination of magnesium, riboflavin and Q10 as prophylactic treatment for migraine.. 130 adult migraineurs (age 18 - 65 years) with ≥ three migraine attacks per month were randomized into two treatment groups: dietary supplementation or placebo in a double-blind fashion. The treatment period was 3 months following a 4 week baseline period without prophylactic treatment. Patients were assessed before randomization and at the end of the 3-month-treatment-phase for days with migraine, migraine pain, burden of disease (HIT-6) and subjective evaluation of efficacy.. Migraine days per month declined from 6.2 days during the baseline period to 4.4 days at the end of the treatment with the supplement and from 6.2.days to 5.2 days in the placebo group (p = 0.23 compared to placebo). The intensity of migraine pain was significantly reduced in the supplement group compared to placebo (p = 0.03). The sum score of the HIT-6 questionnaire was reduced by 4.8 points from 61.9 to 57.1 compared to 2 points in the placebo-group (p = 0.01). The evaluation of efficacy by the patient was better in the supplementation group compared to placebo (p = 0.01).. Treatment with a proprietary supplement containing magnesium, riboflavin and Q10 (Migravent® in Germany, Dolovent® in USA) had an impact on migraine frequency which showed a trend towards statistical significance. Migraine symptoms and burden of disease, however, were statistically significantly reduced compared to placebo in patients with migraine attacks.

    Topics: Adult; Dietary Supplements; Double-Blind Method; Drug Combinations; Female; Germany; Humans; Magnesium; Male; Middle Aged; Migraine Disorders; Riboflavin; Surveys and Questionnaires; Treatment Outcome; Ubiquinone; Vitamins

2015
Ginkgolide B complex efficacy for brief prophylaxis of migraine in school-aged children: an open-label study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2011, Volume: 32, Issue:1

    Primary headaches (migraines and tension-types headaches) are very common in school-aged children. Ginkgolide B, a herbal constituent extract from Ginkgo biloba tree leaves, was considered as a promising pharmacological aid for the treatment of migraine in adult patients because of its modulation of the glutamatergic transmission in the CNS and on antiplatelet activating factor (PAF). The aim of study is to verify the effectiveness and safety of association of Ginkgolide B/Coenzyme Q10/Riboflavin/Magnesium complex for brief prophylaxis in a population of school-aged children with migraine. In our sample after 3 months of treatment with association of Ginkgolide B/Coenzyme Q10/Riboflavin/Magnesium complex, the mean frequency per month of migraine was significantly decreased (9.71 ± 4.33 vs. 4.53 ± 3.96 attacks; p < 0.001). Our findings suggest that in childhood headache management, the use of alternative treatments must be considered not to evoke a placebo effect, but as soft therapy without adverse reactions.

    Topics: Analysis of Variance; Child; Drug Therapy, Combination; Female; Ginkgolides; Humans; Lactones; Magnesium; Male; Migraine Disorders; Riboflavin; Ubiquinone

2011
A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine.
    Cephalalgia : an international journal of headache, 2011, Volume: 31, Issue:8

    To evaluate the efficacy of Coenzyme Q10 (CoQ10) supplementation in the prevention of migraine in children using a placebo-controlled, double-blinded, crossover, add-on trial.. CoQ10 has been demonstrated to have efficacy in migraine prevention in adults but lacks pediatric research with more rigorous methodology. CoQ10 has been observed to be deficient in a significant number of children and adolescents presenting to tertiary headache centers. CoQ10 has the potential to modify both the inflammatory changes that occur during recurrent migraine and the alteration of mitochondrial function. A deficit of CoQ10 could thus affect the response to treatment and clinical characteristics of migraine in children and adults.. One-hundred-and-twenty children and adolescents with migraine headache were randomized in a crossover, double-blind, placebo-controlled, randomized, add-on study to receive a placebo or CoQ10 (100 mg) supplement for 224 days. Data for 76 patients were available at the crossover point and 50 were analysed at the endpoint. Response to treatment, overall headache improvement, and headache disability were assessed.. Both the placebo and CoQ10 groups showed reduced migraine frequency [F(1, 60)=15.68, p<0.001], severity [F(1, 54)=8.09, p=0.006], and duration [F(1, 45)=6.27, p=0.016] over time. CoQ10 treated patients had a significantly greater improvement in frequency from subject reported baseline starting within 4 weeks of initiation. No group differences comparing the first 4 weeks of treatment with the last 4 weeks of treatment were found in migraine frequency [F(1, 60)=2.34, p>0.05], severity [F(1, 54)=0.06, p>0.05], or duration [F(1, 45)=0.14, p>0.05].. Overall, results of the study demonstrate that children and adolescents with migraine improved over time with multidisciplinary, standardized treatment regardless of supplementation with CoQ10 or placebo. There was no difference in headache outcomes between the CoQ10 and placebo groups at day 224. Due to the improvements seen in weeks 1-4, CoQ10 may lead to earlier improvement in headache severity, but given the sample size this conclusion warrants further investigation with a larger sample.

    Topics: Adolescent; Child; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Ubiquinone; Vitamins

2011
Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine.
    Headache, 2007, Volume: 47, Issue:1

    Coenzyme Q10 (CoQ10) has been suggested to be effective in the prevention of migraine, and levels can be quantified with standardized reference ranges.. This study documents the prevalence of CoQ10 deficiency in migraine headache and examines the potential effectiveness of supplementation.. We assessed patients attending a tertiary care center with frequent headaches for CoQ10 deficiency. We recommended patients with low CoQ10 levels begin supplementation with CoQ10 as part of their multidisciplinary treatment plan. We assessed response to treatment including correction of CoQ10 deficiency, overall headache improvement, and headache disability.. CoQ10 was measured in 1550 patients (mean age 13.3 +/- 3.5, range 3 to 22 years). The mean total CoQ10 level was 0.60 +/- 0.20 microg/mL (range 0.21 to 1.77 microg/mL). Of these patients, 32.9% were below the reference range. Patients with low CoQ10 were recommended to start 1 to 3 mg/kg per day of CoQ10 in liquid gel capsule formulation. In a subset of patients who returned for timely follow-up (mean, 97 days), the total CoQ10 level improved to 1.20 +/- 0.59 microg/mL (P < .0001), while the headache frequency improved from 19.2 +/- 10.0 to 12.5 +/- 10.8 (P < .001) and headache disability assessed with PedMIDAS improved from 47.4 +/- 50.6 to 22.8 +/- 30.6 (P < .001).. Deficiency of CoQ10 may be common in pediatric and adolescent migraine. Determination of deficiency and consequent supplementation may result in clinical improvement. Further analysis involving more scientifically rigorous methodology will be required to confirm this observation.

    Topics: Adolescent; Child; Coenzymes; Dietary Supplements; Disability Evaluation; Female; Humans; Male; Migraine Disorders; Treatment Outcome; Ubiquinone

2007
Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial.
    Neurology, 2005, Feb-22, Volume: 64, Issue:4

    Riboflavin, which improves energy metabolism similarly to coenzyme Q10 (CoQ10), is effective in migraine prophylaxis. We compared CoQ10 (3 x 100 mg/day) and placebo in 42 migraine patients in a double-blind, randomized, placebo-controlled trial. CoQ10 was superior to placebo for attack-frequency, headache-days and days-with-nausea in the third treatment month and well tolerated; 50%-responder-rate for attack frequency was 14.4% for placebo and 47.6% for CoQ10 (number-needed-to-treat: 3). CoQ10 is efficacious and well tolerated.

    Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Treatment Outcome; Ubiquinone

2005
Open label trial of coenzyme Q10 as a migraine preventive.
    Cephalalgia : an international journal of headache, 2002, Volume: 22, Issue:2

    The objective was to assess the efficacy of coenzyme Q10 as a preventive treatment for migraine headaches. Thirty-two patients (26 women, 6 men) with a history of episodic migraine with or without aura were treated with coenzyme Q10 at a dose of 150 mg per day. Thirty-one of 32 patients completed the study; 61.3% of patients had a greater than 50% reduction in number of days with migraine headache. The average number of days with migraine during the baseline period was 7.34 and this decreased to 2.95 after 3 months of therapy, which was a statistically significant response (P < 0.0001). Mean reduction in migraine frequency after 1 month of treatment was 13.1% and this increased to 55.3% by the end of 3 months. Mean migraine attack frequency was 4.85 during the baseline period and this decreased to 2.81 attacks by the end of the study period, which was a statistically significant response (P < 0.001). There were no side-effects noted with coenzyme Q10. From this open label investigation coenzyme Q10 appears to be a good migraine preventive. Placebo-controlled trials are now necessary to determine the true efficacy of coenzyme Q10 in migraine prevention.

    Topics: Adult; Coenzymes; Female; Humans; Incidence; Male; Medical Records; Migraine Disorders; Time Factors; Ubiquinone

2002

Other Studies

7 other study(ies) available for ubiquinone and Migraine-Disorders

ArticleYear
An observational study of fixed-dose Tanacetum parthenium nutraceutical preparation for prophylaxis of pediatric headache.
    Italian journal of pediatrics, 2019, Mar-12, Volume: 45, Issue:1

    Migraine is one of the most prevalent chronic pain manifestations of childhood. Despite the multitude of available treatments, parents are often concerned about chronic therapies and pediatricians have insufficient confidence in prescribing prophylactic drugs. Therefore, there is now growing interest for natural supplements used to control recurrent migraine headaches. Such approach may increase acceptance and adherence to long-term prophylaxis therapy in children.. This is an observational multicenter study performed in children (n = 91) with migraine, with (MO) or without aura (MA), or tension-type headache (TTH). A fixed-dose Andrographis paniculata, CoQ10, riboflavin, and magnesium, was administered for 16 weeks. Patients were evaluated at baseline (T0), at week 8 (T1) and at the end of treatment at week 16 (T2). A follow-up period occurred at week 20 (T3) and week 32 (T4).. The herbal supplement significantly reduced the frequency of headaches in TTH patients during treatment period (T0: 11.97 + 1.92 vs T2: 5.13 + 1.93; p < 0.001) and the efficacy was maintained after 16 weeks of treatment withdrawal (T4: 4.46 + 1.75; p < 0.001 vs T0). The frequency of migraine attacks was also reduced in the MO group during treatment (T0: 9.70 + 0.96 vs T2: 4.03 + 0.75; p < 0.01) and after withdrawal (T4: 2.96 + 0.65; p < 0.01 vs T0). Conversely, MA patients showed reduction in migraine's frequency during treatment (T0: 8.74 + 1.91 vs T2: 3.78 + 2.02; p < 0.01) but not at the end of the study (T4: 5.57 + 3.31; p > 0.05 vs T0). TTH patients did not report significant improvement of pain intensity. A significant effect was observed in the MO group during treatment (T0: 3.06 + 0.11 vs T2: 2.14 + 0.19; p < 0.001) and after treatment withdrawal (T4: 2.20 + 0.21; p < 0.001 vs T0). Likewise, MA group showed a significant treatment effect (T0: 2.57 + 0.20 vs T2: 0.86 + 0.45; p < 0.001) and the efficacy persisted at the end of the study (T4: 1.00 + 0.58; p < 0.001 vs T0).. This fixed-dose Tanacetum parthenium preparation improved headache frequency and pain intensity in children affected by TTH. Despite the main limits, this study supports the use of nutraceutical in pediatric headache/migraine.

    Topics: Adolescent; Analysis of Variance; Child; Cohort Studies; Dietary Supplements; Female; Follow-Up Studies; Holistic Health; Humans; Italy; Magnesium; Male; Migraine Disorders; Pain Measurement; Plant Extracts; Plants, Medicinal; Prospective Studies; Riboflavin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Tanacetum parthenium; Tension-Type Headache; Treatment Outcome; Ubiquinone

2019
Commiphora myrra, alternative treatment in migraine prophylaxis: open label prospective pilot study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2018, Volume: 39, Issue:Suppl 1

    Topics: Adolescent; Adult; Commiphora; Drug Combinations; Female; Humans; Male; Middle Aged; Migraine Disorders; Pilot Projects; Prospective Studies; Resins, Plant; Riboflavin; Statistics, Nonparametric; Treatment Outcome; Ubiquinone; Visual Analog Scale; Young Adult

2018
The use of nutraceutics in children's and adolescent's headache.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2017, Volume: 38, Issue:Suppl 1

    Nutraceutics are the most used non-pharmacological remedies for migraine's prophylaxis in children and adolescents. Doctors interested in use of nutraceuticals for a complete treatment of children's headache should be adequately informed on this treatments' efficacy and safety. Actually there is a lack of official guidelines about use of nutraceuticals in migraine's prevention in children and adolescent and there are few studies with limited efficacy evidences. The most used nutraceuticals for adolescent's and children's headache prophylaxis are: magnesium, coenzyme Q10, riboflavin, butterbur, feverfew and melatonin. Further Randomised Controlled Trials are needed for a better effectiveness evaluation in nutraceuticals' use for migraine treatment in child and adolescent.

    Topics: Adolescent; Child; Dietary Supplements; Headache; Humans; Magnesium; Migraine Disorders; Petasites; Tanacetum parthenium; Treatment Outcome; Ubiquinone

2017
A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study.
    BMC complementary and alternative medicine, 2017, Aug-30, Volume: 17, Issue:1

    Feverfew (Tanacetum parthenium L.), magnesium and coenzyme Q10 are frequently used for migraine prophylaxis. Supplementation with a fixed combination of these three agents (Antemig®, PiLeJe) was investigated in an observational study.. Adult patients suffering from migraine according to the criteria of the International Headache Society were enrolled by general practitioners (≥2 migraine attacks during previous month; exclusion of chronic migraine and medication overuse) and after a one-month baseline phase, supplemented with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.. Supplementation significantly reduced the number of days with migraine headache during third month of supplementation compared to baseline phase (1.3 days ±1.5 versus 4.9 days ±2.6, p < 0.0001; n = 68 intention to treat; primary criterion). The decrease was progressive over the period of supplementation and significant from first month (1st month: -2.5 days ±3.1, p < 0.0001; 2nd month: -3 days ±2.8, p < 0.0001). The proportion of patients with a reduction of at least 50% in the number of days with migraine headache was 75% (51/68) after 3 months, with a progressive increase over the period of supplementation (63.2% [43/68] after 1 month and 70.6% [48/68] after 2 months). The proportion of patients with anxiety and depressive symptoms (Hospital Anxiety and Depression Scale) decreased between baseline phase and third month of supplementation from 61.9% (39/63 patients with information available) to 35% (21/60) for depression and from 52.4% (33/63) to 30% (18/60) for anxiety. An improvement of quality of life (Qualité de Vie et Migraine questionnaire) was also observed. The combination was well tolerated.. Results suggest that the proprietary supplement containing feverfew, coenzyme Q10 and magnesium assessed could be beneficial and safe for the prevention of migraine in adult patients and merits further study.. ClinicalTrials.gov: NCT02901756 , retrospectively registered on August 24, 2016.

    Topics: Adolescent; Adult; Aged; Dietary Supplements; Drug Combinations; Female; Humans; Magnesium; Male; Middle Aged; Migraine Disorders; Plant Extracts; Prospective Studies; Quality of Life; Tanacetum parthenium; Ubiquinone; Young Adult

2017
Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs.
    Neurology, 2010, Jan-12, Volume: 74, Issue:2

    Topics: Brain Diseases, Metabolic; Chronic Disease; Disease Progression; DNA, Mitochondrial; Genetic Predisposition to Disease; Haplotypes; Humans; Migraine Disorders; Mitochondrial Diseases; Riboflavin; Thioctic Acid; Ubiquinone; Vitamin B Complex

2010
[The use of noben (idebenone) in the complex treatment of episodic and chronic migraine].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010, Volume: 110, Issue:6

    Topics: Adult; Antioxidants; Chronic Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Migraine Disorders; Treatment Outcome; Ubiquinone

2010
[Coenzyme q10 in childhood: detection methods, reference values and disease-related changes in the coenzyme q10 status].
    Georgian medical news, 2008, Issue:156

    The lipophilic antioxidant coenzyme Q10 is an effective inhibitor of oxidative damage. Furthermore coenzyme Q10 is involved in electron transport related to the mitochondrial respiratorial chain. Because of this double function coenzyme Q10 has become a special role in the group of antioxidants. Little is known about coenzyme Q10 in healthy and sick children. The aim of the study was to determine the role of coenzyme Q10 in the pathophysiological concept of pediatric diseases. At first a HPLC-method for the detection of coenzyme Q10 in plasma, erythrocytes and platelets was developed and age-related reference values for children were established. Based on these reference values the CoQ10 status was measured in different pediatric diseases. By this way various conditions for low coenzyme Q10 plasma values in children could be defined. Furthermore there were different in vivo models developed to define pharmacokinetic and pharmacodynamic characteristics of coenzyme Q10. The established methods and measured data might be a helpful contribution for estimating coenzyme Q10 deficiency and for planning therapeutical studies with coenzyme Q10 in childhood.

    Topics: Antioxidants; Ataxia; Child; Hepatitis; Humans; Migraine Disorders; Mitochondria, Muscle; Mitochondrial Diseases; Oxidative Stress; Severity of Illness Index; Ubiquinone

2008